Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT02336984 | A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04142554 | Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer(LCCC1820) | withdrawn | Phase 1 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Nov 3, 2020 | clinicaltrials |
| NCT03846583 | Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Oct 23, 2020 | clinicaltrials |
| NCT00706615 | Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02547961 | Chimeric Antigen Receptor-Modified T Cells for Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT04332549 | To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer | withdrawn | Phase 1 | 0 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 1 | Jun 1, 2020 | clinicaltrials |
| NCT03400254 | Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")(GLACIER) | withdrawn | Phase 1 / Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT02619669 | Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer | withdrawn | Phase 1 | 0 | Gary SchwartzOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT03721211 | Imaging With [11C]Martinostat in Breast Cancer | withdrawn | Phase 1 | 0 | Christine Elizabeth EdmondsOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT03110445 | Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus(rVV-740CTA) | withdrawn | Phase 1 | 0 | University Hospital, Basel, SwitzerlandOTHER | 0 | Feb 7, 2020 | clinicaltrials |
| NCT02018419 | Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients(MBC) | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03611985 | Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphane™ and Taxanes in Breast Cancer Patients | withdrawn | Phase 1 / Phase 2 | 0 | University of FloridaOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT02988648 | A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter | withdrawn | Phase 1 / Phase 2 | 0 | Yale UniversityOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT03285607 | MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Aug 16, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT03045393 | Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC(IMGN853) | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00006123 | Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT01386502 | CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02915172 | Lenvatinib and Capecitabine in Patients With Advanced Malignancies | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 26, 2017 | clinicaltrials |
| NCT02483871 | Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01361945 | AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Texas Tech University Health Sciences Center, El PasoOTHER | 0 | May 9, 2017 | clinicaltrials |
| NCT00937417 | S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Apr 24, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT00397501 | BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain | withdrawn | Phase 1 / Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02058667 | Reirradiation With Concurrent Paclitaxel for Breast Cancer | withdrawn | Phase 1 | 0 | University of KentuckyOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT01479179 | Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
| NCT00006126 | Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 0 | Nov 13, 2015 | clinicaltrials |
| NCT02396433 | Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers | withdrawn | Phase 1 / Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Aug 25, 2015 | clinicaltrials |
| NCT00704392 | Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors | withdrawn | Phase 1 | 0 | ExelixisINDUSTRY | 1 | Aug 20, 2015 | clinicaltrials |
| NCT00022230 | Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roger Williams Medical CenterOTHER | 1 | May 5, 2015 | clinicaltrials |
| NCT00635245 | CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 0 | Mar 11, 2015 | clinicaltrials |
| NCT00575978 | Hydralazine as Demethylating Agent in Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of ArkansasOTHER | 0 | Mar 4, 2015 | clinicaltrials |
| NCT01320787 | 18-F-Fluoroacetate as PET Imaging Agent | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 23, 2014 | clinicaltrials |
| NCT01741597 | Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | May 30, 2014 | clinicaltrials |
| NCT01539876 | Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Docetaxel(TNFactor) | withdrawn | Phase 1 | 0 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT00074139 | Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 5, 2014 | clinicaltrials |
| NCT01240928 | MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Aug 20, 2013 | clinicaltrials |
| NCT00017537 | Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Aug 5, 2013 | clinicaltrials |
| NCT01614184 | Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of UtahOTHER | 0 | Jul 10, 2013 | clinicaltrials |
| NCT01219907 | Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer | withdrawn | Phase 1 | 0 | University of WashingtonOTHER | 1 | May 17, 2013 | clinicaltrials |
| NCT00903214 | Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer | withdrawn | Phase 1 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Apr 29, 2013 | clinicaltrials |
| NCT01333423 | Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC) | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 26, 2012 | clinicaltrials |
| NCT00627627 | A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer | withdrawn | Phase 1 / Phase 2 | 56 | MedImmune LLCINDUSTRY | 1 | Feb 3, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Apr 30, 2021source: clinicaltrials